Gregory San, MD
Cardiovascular Disease · Greenville, SCNPI 1679565279
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,098 of the $87,986 with a category attached, or 79.7%. 34 manufacturers reported payments, led by Lilly USA, LLC at 56.0% of the total. Reporting peaked in 2019 at $28,237 and has fallen 74.4% since, to $7,242 in 2025. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 579 payments — averaging $151.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$49K
- Boehringer Ingelheim$30K
- Boston Scientific$1K
- Medtronic$878
- Abbott$859
- Johnson & Johnson$854
- plus $5K from 28 others
Across 165 payments — averaging $2068.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$226K
- Boehringer Ingelheim Pharma GmbH & Co.kg$115K
What the payments were for
- Consulting fees$3,7504%
- Speaking & faculty fees$70,09880%
- Travel & lodging$3,1934%
- Food & beverage$10,85112%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 72 | $49,306 |
| Boehringer Ingelheim | 61 | $29,802 |
| Boston Scientific | 16 | $1,141 |
| Medtronic(2 entities) | 51 | $878 |
| Abbott | 25 | $859 |
| Johnson & Johnson | 95 | $854 |
| Amgen | 41 | $776 |
| Novartis | 42 | $652 |
| Abiomed | 11 | $589 |
| AstraZeneca | 23 | $393 |
| Pfizer | 24 | $384 |
| Merck | 21 | $353 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $343 |
| Bayer | 11 | $313 |
| Edwards Lifesciences | 2 | $216 |
| Gilead | 12 | $136 |
| Sanofi-aventis U.S. LLC | 7 | $135 |
| Atricure, Inc. | 4 | $113 |
| E.r. Squibb & Sons, L.L.C. | 2 | $108 |
| Teleflex Medical Canada Inc. | 1 | $97 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Shockwave Medical, Inc | 5 | $75 |
| Amarin Pharma, Inc. | 5 | $70 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 1 | $40 |
| Cvrx, Inc. | 2 | $39 |
| Novo Nordisk | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Cardiovascular Systems Inc. | 2 | $29 |
| Acist Medical Systems, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $18 |
| Terumo Medical Corporation | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$72,651
- Impella$363
- AVVIGO Guidance System$353
- OPTICROSS$277
- Resolute$234
- Xience Sierra Coronary Stent System$153
- Xience V coronary stent system$150
- WATCHMAN FLX$141
- GENERAL - STENTS$131
- Repatha$125
- Kerendia$116
- MitraClip$115
- Edwards SAPIEN 3 Transcatheter Heart Valve$111
- VYNDAQEL$110
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$105
- XARELTO$104
How this compares
$87,986 in reported general payments places this provider in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 550 | $586,886 |
| XareltoRivaroxaban | 217 | $249,870 |
| JardianceEmpagliflozin | 245 | $236,962 |
| Repatha SureclickEvolocumab | 151 | $139,065 |
| EntrestoSacubitril/Valsartan | 122 | $121,802 |
| OzempicSemaglutide | 97 | $95,410 |
| WegovySemaglutide | 36 | $55,662 |
| FarxigaDapagliflozin Propanediol | 35 | $39,000 |
| MounjaroTirzepatide | 21 | $21,489 |
| BrilintaTicagrelor | 12 | $11,332 |
| VascepaIcosapent Ethyl | 15 | $8,568 |
| Valsartan | 271 | $8,074 |
| Metoprolol Succinate | 612 | $7,841 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $6,707 |
| Ranolazine ErRanolazine | 48 | $5,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $384 | $586,886550 claims |
| Johnson & JohnsonXarelto | $854 | $249,870217 claims |
| Boehringer IngelheimJardiance | $29,802 | $236,962245 claims |
| Novo NordiskOzempic, Wegovy | $38 | $151,072133 claims |
| NovartisEntresto | $652 | $121,802122 claims |
| AstraZenecaFarxiga, Brilinta | $393 | $50,33147 claims |
| Lilly USA, LLCMounjaro | $49,306 | $21,48921 claims |
| Esperion Therapeutics, Inc.Nexlizet | $34 | $6,70713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Greenville
- David McNeelyGreenville$78K
- Christopher SalmonGreenville$54K
- Arthur EberlyGreenville$34K
- Tara HolderGreenville$20K
- Dev VazGreenville$14K
- Jon BittrickGreenville$13K
- James MerriamGreenville$11K
- Harold BlanksGreenville$9K
- Arthur SiachosGreenville$9K
- Robert BiedermanCharleston$775K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.